Evaluating the Value of Financial Investment in Prostate Cancer Treatments
-
By
-
Charles L. Bennett
-
Chadi Nabhan
-
September 10, 2026
Clinical Scorecard: Evaluating the Value of Financial Investment in Prostate Cancer Treatments
At a Glance
| Category | Detail |
|---|
| Condition | Prostate Cancer |
| Key Mechanisms | Systemic therapies, particularly second-generation androgen receptor pathway inhibitors, improve pain control, disease progression, and survival. |
| Target Population | Medicare fee-for-service population with prostate cancer. |
| Care Setting | Oncology |
Key Highlights
- Prostate cancer-related spending increased from $504 million to $1.9 billion from 2012 to 2021.
- Systemic therapies accounted for 74% of prostate cancer expenditures in 2021.
- Second-generation androgen receptor pathway inhibitors represented 64% of total prostate cancer expenditures.
Guideline-Based Recommendations
Diagnosis
Management
- Integrate second-generation androgen receptor pathway inhibitors earlier along the disease continuum.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with prostate cancer under Medicare fee-for-service.
Novel systemic treatments have transformed management and improved quality of life.
Clinical Best Practices
- Consider the complete treatment trajectories in assessing prostate cancer's value and economics.
Related Resources & Content
